TY - JOUR
T1 - Study design and methods of the Wells and Enteric disease Transmission (WET) Trial
T2 - a randomised controlled trial
AU - Lee, Debbie
AU - Denno, Donna
AU - Tarr, Phillip
AU - Wu, Jingwei
AU - Stokdyk, Joel P.
AU - Borchardt, Mark
AU - Murphy, Heather M.
N1 - Funding Information:
The authors would like to thank and acknowledge the support of the advisory panel during the development and ongoing execution of the trial. We would like to thank the following advisory panel members: Drs Jack Colford, Tim Wade, Tom Clasen, Lori Holtz, Greg Storch and Karl Linden. We would also like to thank Dr Joe Brown, Joseph Wallace, Lisa Reynolds Fogarty and Meredith Nevers for their review of the protocol. Any use of trade, firm or product names is for descriptive purposes only and does not imply endorsement by the US Government.
Funding Information:
Funding This work was supported by National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award numbers: R34AI127305, R01AI153376. The work was also supported by the Pennsylvania Department of Health's Pennsylvania Commonwealth Universal Research Enhancement Program (PA CURE) Formula Funds 2019 (Grant # 4100083099 to Temple University). The ultraviolet water treatment systems in the study were donated by London, Ontario, Canada based company, Trojan Technologies. None of the sponsors or funders have had any role or authority over the study design, data collection and management, nor will they have any role or authority in the analysis, interpretation of the data or publication of the trial results. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/3/2
Y1 - 2023/3/2
N2 - Introduction The burden of disease attributed to drinking water from private wells is not well characterised. The Wells and Enteric disease Transmission trial is the first randomised controlled trial to estimate the burden of disease that can be attributed to the consumption of untreated private well water. To estimate the attributable incidence of gastrointestinal illness (GI) associated with private well water, we will test if the household treatment of well water by ultraviolet light (active UV device) versus sham (inactive UV device) decreases the incidence of GI in children under 5 years of age. Methods and analysis The trial will enrol (on a rolling basis) 908 families in Pennsylvania, USA, that rely on private wells and have a child 3 years old or younger. Participating families are randomised to either an active whole-house UV device or a sham device. During follow-up, families will respond to weekly text messages to report the presence of signs and symptoms of gastrointestinal or respiratory illness and will be directed to an illness questionnaire when signs/symptoms are present. These data will be used to compare the incidence of waterborne illness between the two study groups. A randomly selected subcohort submits untreated well water samples and biological specimens (stool and saliva) from the participating child in both the presence and absence of signs/symptoms. Samples are analysed for the presence of common waterborne pathogens (stool and water) or immunoconversion to these pathogens (saliva). Ethics Approval has been obtained from Temple University's Institutional Review Board (Protocol 25665). The results of the trial will be published in peer-reviewed journals. Trial registration number NCT04826991.
AB - Introduction The burden of disease attributed to drinking water from private wells is not well characterised. The Wells and Enteric disease Transmission trial is the first randomised controlled trial to estimate the burden of disease that can be attributed to the consumption of untreated private well water. To estimate the attributable incidence of gastrointestinal illness (GI) associated with private well water, we will test if the household treatment of well water by ultraviolet light (active UV device) versus sham (inactive UV device) decreases the incidence of GI in children under 5 years of age. Methods and analysis The trial will enrol (on a rolling basis) 908 families in Pennsylvania, USA, that rely on private wells and have a child 3 years old or younger. Participating families are randomised to either an active whole-house UV device or a sham device. During follow-up, families will respond to weekly text messages to report the presence of signs and symptoms of gastrointestinal or respiratory illness and will be directed to an illness questionnaire when signs/symptoms are present. These data will be used to compare the incidence of waterborne illness between the two study groups. A randomly selected subcohort submits untreated well water samples and biological specimens (stool and saliva) from the participating child in both the presence and absence of signs/symptoms. Samples are analysed for the presence of common waterborne pathogens (stool and water) or immunoconversion to these pathogens (saliva). Ethics Approval has been obtained from Temple University's Institutional Review Board (Protocol 25665). The results of the trial will be published in peer-reviewed journals. Trial registration number NCT04826991.
KW - Community child health
KW - Epidemiology
KW - Gastrointestinal infections
KW - Paediatric gastroenterology
KW - Public health
KW - Respiratory infections
UR - http://www.scopus.com/inward/record.url?scp=85149333684&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2022-068560
DO - 10.1136/bmjopen-2022-068560
M3 - Article
C2 - 36863739
AN - SCOPUS:85149333684
SN - 2044-6055
VL - 13
JO - BMJ Open
JF - BMJ Open
IS - 3
M1 - e068560
ER -